What is the history of Fibromuscular dysplasia?

TL;DR: Fibromuscular dysplasia (FMD) was first described in 1938 by Leadbetter and Burkland, initially identified in the renal arteries of a hypertensive child. Since that discovery, our understanding of Fibromuscular dysplasia has shifted from viewing it as a rare pediatric renal anomaly to recognizing it as a systemic, often underdiagnosed vascular disease frequently affecting middle-aged women.

When was Fibromuscular dysplasia first identified?

The medical history of Fibromuscular dysplasia began in 1938 when Leadbetter and Burkland reported a case of a 5-year-old boy with severe hypertension caused by a narrowing of the renal artery. At the time, the condition was considered an extremely rare pediatric curiosity. It wasn't until the 1960s, with the advent of more sophisticated angiography, that clinicians began to realize Fibromuscular dysplasia was actually a more common cause of secondary hypertension in adults, particularly women, than previously suspected.

How has our understanding of Fibromuscular dysplasia evolved?

For decades, medical literature focused almost exclusively on the "string of beads" appearance seen in renal arteries. Historically, there were several misconceptions, including the belief that Fibromuscular dysplasia was a localized disease. Modern imaging and systemic screening have corrected this, revealing that the condition can affect almost any arterial bed, including the carotid, vertebral, and iliac arteries. We now categorize the disease into two main types: multifocal (the classic "beaded" appearance) and focal (a single, often longer, tubular stenosis).

What were the major milestones in treatment?

The management of Fibromuscular dysplasia has moved away from invasive open surgery toward less traumatic, percutaneous interventions. Key milestones include:

• 1960s-1970s: Initial reliance on open surgical revascularization for renal artery stenosis.


• 1978: The introduction of Percutaneous Transluminal Angioplasty (PTA) by Andreas Grüntzig, which revolutionized the treatment of Fibromuscular dysplasia by allowing physicians to open narrowed vessels without major surgery.


• Modern Era: A shift toward medical management using antiplatelet therapy and blood pressure control, with stenting reserved only for specific complications like artery dissection or aneurysm.

How have technology and genetics changed the landscape?

The integration of advanced vascular imaging, such as CT angiography (CTA) and MR angiography (MRA), has drastically increased the detection rate of Fibromuscular dysplasia. Furthermore, the FMD International Registry and modern genetic studies have provided evidence of a genetic predisposition. While we have not identified a single "FMD gene," researchers have discovered variants in the PHACTR1 gene, which is strongly associated with the disease. This has transformed Fibromuscular dysplasia from a "mysterious" vascular anomaly into a condition currently being studied through the lens of vascular biology and genomics.

The growth of patient advocacy

Historically, patients with Fibromuscular dysplasia felt isolated due to the disease's rarity and the lack of specialized centers. The landscape changed significantly with the formation of global patient organizations and the 132 members within the DiseaseMaps community who share their experiences. These platforms have shifted the focus toward patient-centered research, ensuring that the lived experience of fatigue, pulsatile tinnitus, and arterial dissection informs clinical care guidelines.

Next steps

• Consult a vascular medicine specialist or an interventional radiologist experienced in Fibromuscular dysplasia.


• Request a baseline head-to-pelvis CTA or MRA to screen for aneurysms or dissections if you have been diagnosed with renal or carotid FMD.


• Join the DiseaseMaps.org community to connect with other patients and share your medical journey.


• Monitor blood pressure regularly, as hypertension is the most common clinical finding in this patient population.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

• National Institutes of Health (NIH) Genetic and Rare Diseases Information Center (GARD): Fibromuscular dysplasia.


• Orphanet: Fibromuscular dysplasia (ORPHA:3338).


• The FMD Society of America: Clinical History and Research Updates.


• OMIM (Online Mendelian Inheritance in Man): Fibromuscular dysplasia (Entry #135580).